104+ Funded Biotech & Life Science Startups — $21.1B Raised

Biotech funding in 2025-2026 is experiencing a resurgence after the sector-wide downturn of 2023-2024. Our dataset tracks 81 biotech companies that raised a combined $21.1B at a $60M median — the second-highest median of any vertical, behind only defense. The US accounts for 63 of 81 companies, with the UK (7) as the leading international hub. AI-driven drug discovery platforms are commanding the largest rounds — 24 Series A biotech companies raised a staggering $17.7B at a $60M median, reflecting the capital intensity of bringing AI-generated clinical candidates to market. Gene therapy, cell therapy, and novel drug delivery mechanisms continue to attract significant capital. The regulatory environment is evolving favorably, with the FDA implementing accelerated review pathways for AI-assisted drug development. Longevity science is emerging as a distinct investment category, with aging-focused startups attracting both VC and strategic pharmaceutical investment. For sales teams, biotech companies have unique purchasing patterns. Laboratory equipment, cloud computing for genomic analysis, compliance software, and collaboration tools are common purchases. Decision-making is distributed between scientific leadership (CSO) and operational leadership (COO/VP Operations). Sales cycles are longer but deal sizes are substantial — the $21.1B aggregate makes this a deep-pocketed vertical.